clindamicina qualipharm 600mg/4ml solución inyectable i.m./i.v.
laboratorio qualipharm, s.a. - clindamicina (fosfato) - clindamicina (fosfato)....150.00 mg
ceftriaxona qualipharm 1g polvo para solucion inyectable i.v.
laboratorio qualipharm, s.a. - ceftriaxona (sÓdica) - ceftriaxona (sÓdica)....1.00 g
cefotaxima qualipharm 1g/vial polvo para solución inyectable i.m., i.v.
laboratorio qualipharm, s.a. - cefotaxima (sÓdica) - cefotaxima (sÓdica)....1.00 g
nafazolina clorhidrato qualipharm al 0.1 % solución oftálmica.
laboratorio qualipharm, s.a. - nafazolina clorhidrato - nafazolina clorhidrato....1.00 mg
oxacilina qualipharm 1 g polvo para solución inyectable i.m., i.v.
laboratorio qualipharm, s.a. - oxacilina (sÓdica) - oxacilina (sÓdica)....1 g
levofloxacina qualipharm 500 mg/ 100 ml solución inyectable infusion i.v.
laboratorio qualipharm, s.a. - levofloxacina (hemihidrato) - levofloxacina (hemihidrato)....5.00 mg.
qualiphar megatone plus combination tablet
triangle medical trading l.l.c. belgium - 30's [3x10's blister] - tablet - combination - nutrition , blood-vitamins, nutrition , blood-minerals, nutrition , blood-natural source - see indication field for description
chlorpromazine injection bp
laborate pharmaceuticals india limited laborate pharmaceuticals india limited e-11 - chlorpromazine injection bp - injection - chlorpromazine hydrochloride bp 25mg - antipsychotics: phenothiazineswith aliphatic
chlorpromazine injection bp
nestor pharmaceuticals limited po box : 66829-00800 nairobi kenya - chlorpromazine hydrochloride - injection - 25 mg/ ml - antipsychotics: phenothiazineswith aliphatic
desvenlafaxine tablet, extended release
intellipharmaceutics corp. - desvenlafaxine succinate (unii: zb22enf0xr) (desvenlafaxine - unii:ng99554anw) - desvenlafaxine extended-release tablets, is indicated for the treatment of adults with major depressive disorder (mdd) [see clinical studies (14) ]. •hypersensitivity to desvenlafaxine succinate, venlafaxine hydrochloride or to any excipients in the desvenlafaxine extended-release tablets formulation. angioedema has been reported in patients treated with desvenlafaxine extended-release tablets [see adverse reactions (6.1) ]. •the use of maois intended to treat psychiatric disorders with desvenlafaxine extended-release tablets or within 7 days of stopping treatment with desvenlafaxine extended-release tablets is contraindicated because of an increased risk of serotonin syndrome. the use of desvenlafaxine extended-release tablets within 14 days of stopping an maoi intended to treat psychiatric disorders is also contraindicated [see dosage and administration (2.7) and warnings and precautions (5.2) ]. •starting desvenlafaxine extended-release tablets in a patient who is being treated with maois such as